1. Scrip

Oculis’s OCS-01 Sparkles Treating Front-Of-Eye Inflammation

Swiss Biotech To Now Talk With FDA On Two Phase III Designs

 
• By Sten Stovall

Oculis’s eyedrop OCS-01 showed high efficacy treating post-cataract inflammation in front of the eye, adding to its effective use in back-of-the-eye conditions.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Positive Phase II front-of-the-eye data builds on good back-of-eye disease results. • Source: Shutterstock

With two successful Phase II programs in hand for its lead ocular therapy, Swiss biotech Oculis will now engage with the US Food and Drug Administration to agree a path forward and the design of pivotal studies assessing its daily OCS-01 eyedrop as a treatment for both inflammation and pain following cataract surgery as well as for diabetic macular edema (DME).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D